Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on AnaptysBio Inc (ANAB) today. The company’s shares closed last Monday at $34.99, close to its 52-week low of $34.51.
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -12.4% and a 25.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on AnaptysBio Inc is a Moderate Buy with an average price target of $113.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $100.97 and a one-year low of $34.51. Currently, AnaptysBio Inc has an average volume of 278.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
